• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Impact of molecular point-of-care testing on clinical management and in-hospital costs of patients suspected of influenza or RSV infection: a modeling

tetano

Editor, Senior Moderator
J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25479. [Epub ahead of print]
[h=1]Impact of molecular point-of-care testing on clinical management and in-hospital costs of patients suspected of influenza or RSV infection: a modeling study.[/h] Rahamat-Langendoen J[SUP]1[/SUP], Groenewoud H[SUP]2[/SUP], Kuijpers J[SUP]1[/SUP], Melchers WJG[SUP]1[/SUP], van der Wilt GJ[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] At hospital admission, patients suspected of infection with influenza or respiratory syncytial virus (RSV) are placed in isolation, pending the outcome of diagnostics. In a significant number, isolated care proves unnecessary. We investigated the potential impact of molecular point-of-care (POC) diagnostics on patient management and in-hospital costs.
[h=4]METHOD:[/h] Prospective collection of data on resource utilization within the hospital from consecutive patients18 years or older presenting at our university medical center with symptoms of respiratory tract infection from December 2016 to April 2017. A cost analysis was conducted using Markov modeling comparing the actual course of events (based on routine diagnostic tests) with two hypothetical scenarios: when POC would impact time to diagnosis only (scenario 1) or on discharge from hospital, too (scenario 2).
[h=4]RESULTS:[/h] 283 Patients were included, of whom 217 (76,7%) were admitted. Influenza and RSV were detected in 31% and 7% of the patients, respectively. 54% of patients tested negative, of which 79% were kept in isolated care waiting for test results, with median duration of 24 hours. Median length of stay was 6.0 days. Mean total in-hospital costs per patient were ? 5,243. Introducing POC would lower mean costs per patient to ? 4,904 (scenario 1) and ? 4,206 (scenario 2). At hospital level, this would result in a total cost reduction of ? 95,937 to ? 293,471 in a single influenza season.
[h=4]CONCLUSIONS:[/h] Introducing POC testing for patients presenting with symptoms of viral respiratory tract infection can reduce time-to-diagnosis, hospital stay and, thereby, in-hospital costs. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


[h=4]KEYWORDS:[/h] cost benefit; influenza virus; rapid detection; respiratory syncytial virus

PMID: 30950066 DOI: 10.1002/jmv.25479
 
Back
Top Bottom